Navigation Links
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Date:4/17/2008

WOODCLIFF LAKE, N.J., April 17 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Robert Laverty as Vice President of U.S. Corporate Communications. In this newly created position, Mr. Laverty will be responsible for overseeing and coordinating all of Eisai's corporate communications strategies and activities in the United States.

Mr. Laverty brings to Eisai more than 22 years of global corporate, product, policy and research and development communications experience in the pharmaceutical industry. Most recently, he served as Vice President, Global Communications, Malaria Initiatives for Novartis AG, where he oversaw all global communications supporting the company's malaria initiative in the developing world. In addition, Mr. Laverty has held several other executive titles at Novartis Pharmaceuticals Corp, including Vice President, External Communication and Vice President, Global Pharma Media Relations.

Earlier in his career, Mr. Laverty held a number of progressively responsible positions in corporate policy, corporate affairs, and product public affairs at Bristol-Myers Squibb Company. He holds a Bachelor of Science degree in pharmacy from St. John's University, Jamaica, New York.

"Mr. Laverty is a welcome addition to our company and will be instrumental in strengthening Eisai's visibility and presence in the U.S. as a top-20 pharmaceutical company," said Lonnel Coats, President & COO, Eisai Corporation of North America. "With his more than two decades of senior communications expertise in the global pharmaceutical industry, Mr. Laverty's contributions to our company will be invaluable, as we continue to fulfill our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit http://www.eisai.com.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DARA Announces Surgi-Vision Agreement with Boston Scientific Corporation
2. Torchmark Corporation Reports First Quarter 2008 Results
3. Digirad Corporation to Release First Quarter Financial Results on April 24, 2008
4. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
5. Microflex Corporation Launches New Website
6. Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics
7. Zipfizz(R) Announces Distribution Deal With the Odom Corporation
8. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
9. BioElectronics Corporations New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
10. Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice
11. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: